Trial · NCT04533997
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Diuresis volume (ml) | 3 hours after treatment | Total diuresis volume after 3 hours of therapy administration |
| Secondary | Weight difference (kg) | 3 hours | Difference of weight 3 hours after the start of treatment |
| Secondary | Weight difference (kg) | 7 days | Difference of weight 7 days after the start of treatment |
| Secondary | Change in composite congestion score | 7 days | Composite of orthopnoea (0-3), jugular venous distension (0-3), lower limb oedema (0-3). Higher score: worse congestion |
| Secondary | Change in Inferior cava vein diameter (mm) | 7 days | Change in Inferior cava vein diameter (mm) 7 days after treatment |
| Secondary | Change in Number of fields with more than 3 B-lines in lung ultrasound | 7 days | Change in Number of fields with more than 3 B-lines in lung ultrasound 7 days after treatment |
| Secondary | Change in New York Heart Association and Visual Analogue Scale | 7 days | Visual Analogue Scale from 0 (worst state of health) to 100 (best state of health) |
| Secondary | Change in NTproBNP and Cancer Antigen 125 levels | 7 days | Change in NTproBNP and Cancer Antigen 125 levels 7 days after treatment |
| Secondary | Change in Hemoconcentration Parameters | 7 days | Hematocrit, Albumin and total Proteins |
| Secondary | Change in Urinary Sodium | 7 days | Change in Urinary Sodium measured in a spot urinary sample |
| Secondary | Adverse Events | 7 days | Need of new intravenous diuretic (outpatient clinic or emergency department). Heart Failure hospitalization. Cardiovascular mortality. All-Cause mortality or hospitalization. Worsening of kidney function: defined as an increase in creatinine ≥ 0.3 mg / dl. Electrolyte abnormalities defined as hypokalemia (K+ less than 3.5 milliequivalent / L) or hyperkalemia (K+ greater than 5.5 milliequivalent /L) |
| Secondary | Adverse Events | 30 days | Need of new intravenous diuretic (outpatient clinic or emergency department). Heart Failure hospitalization. Cardiovascular mortality. All-Cause mortality or hospitalization. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04533997/registered